Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve outcomes in cancer treatment
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve outcomes in cancer treatment.
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve outcomes in cancer treatment
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve outcomes in cancer treatment.